Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836
Kort samengevat
Phase 2a study to evaluate safety and immunogenicity of a booster dose of influenza vaccine candidate OVX836, three to five years after initial administration Enrollment of over 150 participants
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij FinanzNachrichten.de.
Lees het volledige bericht ↗